AtriCure, Inc.
Rank #54HypergrowthATRC · Nasdaq · Healthcare
AtriCure, Inc. (ATRC) — Rank #54 by gross profitability (GP/assets 0.59) · ROE -2.2% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0001323885 · all metrics point-in-time as of the filing date.
About
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Show moreShow less
It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel.
The company was incorporated in 2000 and is headquartered in Mason, Ohio.
- Industry
- Medical Instruments & Supplies
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- atricure.com
Financials
Strengthening
Direction over 5 fiscal years
- Free cash flowimproving
- Gross marginstable
- Gross profitabilitystable
- Net cashimproving
- Operating marginimproving
- Return on equityimproving
- Share count (dilution)improving
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2018-12-31filed 2019-03-01 | 2017-12-31filed 2018-02-28 | 2016-12-31filed 2017-03-08 | 2015-12-31filed 2016-02-29 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 201.6 | 174.7 | 155.1 | 129.8 |
| Revenue growth (YoY) | 15.4% | 12.6% | 19.5% | 20.8% |
| Gross profit | 147.1 | 126.2 | 111.1 | 92.9 |
| Gross margin | 73.0% | 72.2% | 71.6% | 71.6% |
| Net income | (21.1) | (26.9) | (33.3) | (27.2) |
| Net margin | -10.5% | -15.4% | -21.5% | -21.0% |
| Cash flow | ||||
| Operating cash flow | (4.2) | (8.9) | (15.1) | (7.8) |
| Capital expenditures | 6.2 | 6.4 | 7.7 | 13.4 |
| Free cash flow | (10.4) | (15.3) | (22.8) | (21.3) |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?